Home › Funds › Elmind Capital, LP › STRO
Elmind Capital, LP position in STRO
SUTRO BIOPHARMA INC · Health Care
Elmind Capital, LP reported holding 228,265 shares of STRO (SUTRO BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$3.7M, representing 0.91% of its reported portfolio and ranking #23 among its reported holdings. Elmind Capital, LP has disclosed STRO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's STRO position evolved
Elmind Capital, LP first disclosed a stake in STRO in Q2 2026 at 32,037 shares (US$1.1M). The position peaked in Q3 2026 at 228,265 shares, worth US$3.7M. Across 2 filings, Elmind Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 228,265 shares valued at US$3.7M — an increase of 196,228 shares quarter over quarter.. Notable position changes include a 613% increase in Q3 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 32.04K | $1.06M | New |
| Q3 2026 | 228.26K | $3.68M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STRO and 13F data
STRO (SUTRO BIOPHARMA INC) is a Health Care company. 34 other funds we track also report a position in STRO — the largest reported positions include BVF INC/IL (US$20.2M), Affinity Asset Advisors, LLC (US$18.6M), Samsara BioCapital, LLC (US$17.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STRO
- BVF INC/IL 1.25M sh · $20.17M · Q3 2026
- Affinity Asset Advisors, LLC 1.15M sh · $18.57M · Q3 2026
- Samsara BioCapital, LLC 1.06M sh · $17.12M · Q3 2026
- PERCEPTIVE ADVISORS LLC 970.85K sh · $15.64M · Q3 2026
- Kynam Capital Management, LP 872.56K sh · $14.06M · Q3 2026
- Velan Capital Investment Management LP 510.04K sh · $8.22M · Q3 2026
- Merck & Co., Inc. 272.35K sh · $4.39M · Q3 2026
- KVP Capital Advisors, LP 226.57K sh · $3.65M · Q3 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held STRO?
Elmind Capital, LP has disclosed STRO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Elmind Capital, LP's current position in STRO?
As of Q3 2026, Elmind Capital, LP holds 228.26K shares of STRO (SUTRO BIOPHARMA INC), valued at $3.68M, representing 0.91% of its reported portfolio and ranking #23.
Has Elmind Capital, LP been buying or selling STRO?
In the latest 13F filing (Q3 2026), Elmind Capital, LP increased its position in STRO. The position peaked in Q3 2026 at 228.26K shares.
Which other funds hold STRO?
Other major institutional holders of STRO include BVF INC/IL, Affinity Asset Advisors, LLC, Samsara BioCapital, LLC, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.